Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Operating Leases (2019 - 2025)

Heron Therapeutics (HRTX) has disclosed Operating Leases for 7 consecutive years, with $780000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Leases rose 49.43% year-over-year to $780000.0, compared with a TTM value of $780000.0 through Sep 2025, up 49.43%, and an annual FY2023 reading of $2.8 million, down 49.08% over the prior year.
  • Operating Leases was $780000.0 for Q3 2025 at Heron Therapeutics, down from $1.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $13.8 million in Q1 2021 and bottomed at $522000.0 in Q3 2024.
  • Average Operating Leases over 5 years is $5.5 million, with a median of $4.8 million recorded in 2023.
  • The sharpest move saw Operating Leases tumbled 85.24% in 2024, then skyrocketed 49.43% in 2025.
  • Year by year, Operating Leases stood at $8.0 million in 2021, then crashed by 31.23% to $5.5 million in 2022, then plummeted by 49.08% to $2.8 million in 2023, then tumbled by 81.36% to $522000.0 in 2024, then surged by 49.43% to $780000.0 in 2025.
  • Business Quant data shows Operating Leases for HRTX at $780000.0 in Q3 2025, $1.5 million in Q2 2025, and $522000.0 in Q3 2024.